Literature DB >> 22186971

UDP-N-acetyl-α-D-galactosamine:polypeptide N-acetylgalactosaminyltransferases: completion of the family tree.

Jayalakshmi Raman1, Yu Guan, Cynthia L Perrine, Thomas A Gerken, Lawrence A Tabak.   

Abstract

The formation of mucin-type O-glycans is initiated by an evolutionarily conserved family of enzymes, the UDP-N-acetyl-α-D-galactosamine:polypeptide N-acetylgalactosaminyltransferases (GalNAc-Ts). The human genome encodes 20 transferases; 17 of which have been characterized functionally. The complexity of the GalNAc-T family reflects the differential patterns of expression among the individual enzyme isoforms and the unique substrate specificities which are required to form the dense arrays of glycans that are essential for mucin function. We report the expression patterns and enzymatic activity of the remaining three members of the family and the further characterization of a recently reported isoform, GalNAc-T17. One isoform, GalNAcT-16 that is most homologous to GalNAc-T14, is widely expressed (abundantly in the heart) and has robust polypeptide transferase activity. The second isoform GalNAc-T18, most similar to GalNAc-T8, -T9 and -T19, completes a discrete subfamily of GalNAc-Ts. It is widely expressed and has low, albeit detectable, activity. The final isoform, GalNAc-T20, is most homologous to GalNAc-T11 but lacks a lectin domain and has no detectable transferase activity with the panel of substrates tested. We have also identified and characterized enzymatically active splice variants of GalNAc-T13 that differ in the sequence of their lectin domain. The variants differ in their affinities for glycopeptide substrates. Our findings provide a comprehensive view of the complexities of mucin-type O-glycan formation and provide insight into the underlying mechanisms employed to heavily decorate mucins and mucin-like domains with carbohydrate.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22186971      PMCID: PMC3336867          DOI: 10.1093/glycob/cwr183

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  35 in total

Review 1.  Innate immunity and mucus structure and function.

Authors:  John K Sheehan; Mehmet Kesimer; Raymond Pickles
Journal:  Novartis Found Symp       Date:  2006

Review 2.  Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways.

Authors:  Kermit L Carraway; Melanie Funes; Heather C Workman; Colleen Sweeney
Journal:  Curr Top Dev Biol       Date:  2007       Impact factor: 4.897

3.  Dynamic association between the catalytic and lectin domains of human UDP-GalNAc:polypeptide alpha-N-acetylgalactosaminyltransferase-2.

Authors:  Timothy A Fritz; Jayalakshmi Raman; Lawrence A Tabak
Journal:  J Biol Chem       Date:  2006-01-24       Impact factor: 5.157

Review 4.  Signaling mucins: the new kids on the MAPK block.

Authors:  Paul J Cullen
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2007       Impact factor: 1.807

Review 5.  Cell surface-associated mucins in signal transduction.

Authors:  Pankaj K Singh; Michael A Hollingsworth
Journal:  Trends Cell Biol       Date:  2006-08-09       Impact factor: 20.808

6.  Characterization of a UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase that displays glycopeptide N-acetylgalactosaminyltransferase activity.

Authors:  K G Ten Hagen; D Tetaert; F K Hagen; C Richet; T M Beres; J Gagnon; M M Balys; B VanWuyckhuyse; G S Bedi; P Degand; L A Tabak
Journal:  J Biol Chem       Date:  1999-09-24       Impact factor: 5.157

7.  Cloning and expression of a brain-specific putative UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase gene.

Authors:  Naosuke Nakamura; Shinya Toba; Mitsuharu Hirai; Shinichi Morishita; Tadahisa Mikami; Morichika Konishi; Nobuyuki Itoh; Akira Kurosaka
Journal:  Biol Pharm Bull       Date:  2005-03       Impact factor: 2.233

8.  Structural basis of carbohydrate transfer activity by human UDP-GalNAc: polypeptide alpha-N-acetylgalactosaminyltransferase (pp-GalNAc-T10).

Authors:  Tomomi Kubota; Tomoo Shiba; Shigemi Sugioka; Sanae Furukawa; Hiromichi Sawaki; Ryuich Kato; Soichi Wakatsuki; Hisashi Narimatsu
Journal:  J Mol Biol       Date:  2006-04-19       Impact factor: 5.469

9.  Site-specific core 1 O-glycosylation pattern of the porcine submaxillary gland mucin tandem repeat. Evidence for the modulation of glycan length by peptide sequence.

Authors:  T A Gerken; C L Owens; M Pasumarthy
Journal:  J Biol Chem       Date:  1998-10-09       Impact factor: 5.157

10.  Localization of three human polypeptide GalNAc-transferases in HeLa cells suggests initiation of O-linked glycosylation throughout the Golgi apparatus.

Authors:  S Röttger; J White; H H Wandall; J C Olivo; A Stark; E P Bennett; C Whitehouse; E G Berger; H Clausen; T Nilsson
Journal:  J Cell Sci       Date:  1998-01       Impact factor: 5.285

View more
  44 in total

1.  Moving the O-glycoproteome from form to function.

Authors:  Jacques U Baenziger
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-01       Impact factor: 11.205

2.  Probing polypeptide GalNAc-transferase isoform substrate specificities by in vitro analysis.

Authors:  Yun Kong; Hiren J Joshi; Katrine Ter-Borch Gram Schjoldager; Thomas Daugbjerg Madsen; Thomas A Gerken; Malene B Vester-Christensen; Hans H Wandall; Eric Paul Bennett; Steven B Levery; Sergey Y Vakhrushev; Henrik Clausen
Journal:  Glycobiology       Date:  2014-08-25       Impact factor: 4.313

3.  O-glycosylation on cerebrospinal fluid and plasma apolipoprotein E differs in the lipid-binding domain.

Authors:  Sarah A Flowers; Oliver C Grant; Robert J Woods; G William Rebeck
Journal:  Glycobiology       Date:  2020-01-28       Impact factor: 4.313

4.  Differential splicing of the lectin domain of an O-glycosyltransferase modulates both peptide and glycopeptide preferences.

Authors:  Carolyn May; Suena Ji; Zulfeqhar A Syed; Leslie Revoredo; Earnest James Paul Daniel; Thomas A Gerken; Lawrence A Tabak; Nadine L Samara; Kelly G Ten Hagen
Journal:  J Biol Chem       Date:  2020-07-15       Impact factor: 5.157

Review 5.  Mucin-type O-glycosylation during development.

Authors:  Duy T Tran; Kelly G Ten Hagen
Journal:  J Biol Chem       Date:  2013-01-17       Impact factor: 5.157

6.  Not so sweet malignant transformation.

Authors:  Jacques U Baenziger
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-16       Impact factor: 11.205

7.  The GALNTL6 Gene rs558129 Polymorphism Is Associated With Power Performance.

Authors:  Julen Díaz Ramírez; Jesús Álvarez-Herms; Arkaitz Castañeda-Babarro; Jon Larruskain; Xabier Ramírez de la Piscina; Oleg V Borisov; Ekaterina A Semenova; Elena S Kostryukova; Nikolay A Kulemin; Oleg N Andryushchenko; Andrey K Larin; Liliya B Andryushchenko; Edward V Generozov; Ildus I Ahmetov; Adrian Odriozola
Journal:  J Strength Cond Res       Date:  2020-09-16       Impact factor: 3.775

8.  Polypeptide N-Acetylgalactosaminyltransferase 13 Contributes to Neurogenesis via Stabilizing the Mucin-type O-Glycoprotein Podoplanin.

Authors:  Yingjiao Xu; Wenjie Pang; Jishun Lu; Aidong Shan; Yan Zhang
Journal:  J Biol Chem       Date:  2016-09-14       Impact factor: 5.157

9.  Mucin-type O-glycosylation is controlled by short- and long-range glycopeptide substrate recognition that varies among members of the polypeptide GalNAc transferase family.

Authors:  Leslie Revoredo; Shengjun Wang; Eric Paul Bennett; Henrik Clausen; Kelley W Moremen; Donald L Jarvis; Kelly G Ten Hagen; Lawrence A Tabak; Thomas A Gerken
Journal:  Glycobiology       Date:  2015-11-26       Impact factor: 4.313

10.  The lectin domain of the polypeptide GalNAc transferase family of glycosyltransferases (ppGalNAc Ts) acts as a switch directing glycopeptide substrate glycosylation in an N- or C-terminal direction, further controlling mucin type O-glycosylation.

Authors:  Thomas A Gerken; Leslie Revoredo; Joseph J C Thome; Lawrence A Tabak; Malene Bech Vester-Christensen; Henrik Clausen; Gagandeep K Gahlay; Donald L Jarvis; Roy W Johnson; Heather A Moniz; Kelley Moremen
Journal:  J Biol Chem       Date:  2013-05-20       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.